Loading...
Market
What will be the impact on telehealth businesses from DEA's waiver decision by June 2025?
2
Resolution / Starting Odds
Growth • 25%
Decline • 25%
Stagnation • 25%
Diversification • 25%
Financial reports and business news articles
Story
Telehealth Providers Urge DEA to Extend Pandemic Waiver for Prescribing Controlled Substances
Oct 10, 2024, 01:42 PM
Telehealth providers prescribing controlled substances face chaos as pandemic-era flexibilities are set to end in just months, with no new rules in sight. The DEA had granted a 2020 legal waiver allowing telehealth startups to prescribe controlled substances without requiring an in-person doctor visit. With these flexibilities ending, telehealth leaders are pressing the DEA to extend the waiver, blaming the agency for putting their businesses at serious risk. Silicon Valley telehealth startups, launched during the pandemic, are now engaging in policy advocacy for the first time.
View original story
Similar markets
Permanent rule allowing telehealth prescribing • 25%
Temporary extension beyond 2025 • 25%
Reversion to pre-COVID rules • 25%
Other • 25%
Patients • 25%
Telehealth providers • 25%
Pharmaceutical companies • 25%
Other • 25%
Addiction treatment • 25%
ADHD medication • 25%
Opioid prescriptions • 25%
Other controlled substances • 25%
Healthcare industry • 25%
Pharmaceutical companies • 25%
Public health advocacy groups • 25%
Government agencies • 25%
Trump Administration • 33%
Next Administration • 33%
No permanent policy by end of 2025 • 34%
Stricter regulations • 25%
Looser regulations • 25%
No change • 25%
Mixed outcomes • 25%